Chemomab Therapeutics Ltd
For the period ended Oct 11, 2024. Filed Oct 11, 2024.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Oct 11, 2024 · Filed Oct 11, 2024
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · ADDITIONAL INFORMATION
ADDITIONAL INFORMATION
Our Annual Report filed with the SEC on March 28, 2024, and other filings with the SEC, including reports regarding the Company’s quarterly business and financial results, are available for viewing and downloading on the SEC’s website at www.sec.gov as well as under the “Investor Relations” section of the Company’s website athttps://investors.chemomab.com/. Shareholders may obtain a copy of these documents without charge athttps://investors.chemomab.com/.
The Company is subject to the information reporting requirements of the Exchange Act applicable to foreign private issuers. The Company fulfills these requirements by filing reports with the SEC. The Company’s filings with the SEC are available to the public on the SEC’s website at www.sec.gov. As a foreign private issuer, the Company is exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements. The circulation of this proxy statement should not be taken as an admission that the Company is subject to those proxy rules.
By Order of the Board of Directors
/s/ Dr. Nissim Darvish
Chairperson of the Board of Directors
Dated: October 11, 2024
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.